Huvepharma® announces Optigrid®45 medicated feed combination approvals
Posted on January 28, 2021
Global animal health company Huvepharma’s Optigrid® 45, ractopamine hydrochloride Type A medicated article a feed additive used to promote weight gain and improve feed efficiency in finishing feedlot cattle, has received U.S. Food & Drug Administration approval for combination use with other drug feed additive products in the manufacture of Type B and C medicated feeds.
Optigrid® 45, which is comprised of the active ingredient ractopamine hydrochloride, can be fed as a complete feed or top dress feed to cattle fed in confinement for slaughter during the last 28-48 days on feed prior to harvest. The combination approvals allow Optigrid® 45 to be used with other feed additives commonly fed to feedlot cattle, including monensin, tylosin and melengestrol.
The four specific combinations receiving FDA approval include Optigrid® 45 with Monovet® 90 (monensin Type A medicated article); Optigrid® 45 with Monovet® 90 and Tylovet® (tylosin phosphate Type A Medicated Article); Optigrid® 45 with Monovet® 90 and MGA® (melengestrol); and Optigrid® 45 with Monovet® 90, Tylovet, and MGA.
“With the continued need for efficiency in beef production, we are pleased to bring these medicated feed additive combinations with Optigrid 45 to the cattle industry,” said head of U.S. sales and marketing, Rick Cozzitorto.
Huvepharma has been active in the U.S. animal health market since 2005 providing products for poultry, swine and cattle markets. The company received FDA approval for Optigrid® 45 in June 2020.
For more information, please contact your Huvepharma sales representative and/or Huvepharma’s Customer Service team at 877-994-4883.
Huvepharma is a global pharmaceutical company with a focus on developing, manufacturing and marketing human and animal health products. A privately-owned company headquartered in Sofia, Bulgaria, Huvepharma’s U.S. headquarter are located in Peachtree City, GA.
Huvepharma, Monovet, and Tylovet are registered trademarks of Huvepharma EOOD.
MGA is a registered trademark of Zoetis.
IMPORTANT SAFETY INFORMATION OPTIGRID® 45 (ractopamine hydrochloride Type A medicated article): Not for human use. For use in feeds for cattle fed in confinement for slaughter. Not for animals intended for breeding. No withdrawal is necessary if directions are followed. The active ingredient in Optigrid 45, ractopamine hydrochloride, is a Beta-adrenergic agonist. Individuals with cardiovascular disease should exercise special caution to avoid exposure. Not for use in humans. Keep out of the reach of children. The Optigrid 45 formulation (Type A Medicated Article) poses a low dust potential under usual conditions of handling and mixing. When mixing and handling Optigrid 45 use protective clothing, impervious gloves, protective eye wear, and a NIOSH-approved dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse eyes thoroughly with water. If irritation persists, seek medical attention. The Safety Data Sheet (SDS) contains more detailed occupational safety information. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or http://www.fda.gov/reportanimalae. To report suspected adverse drug events, for technical assistance or to obtain a copy of the SDS, contact Huvepharma, Inc. at 1-877-994-4883 or www.huvepharma.us. View product label here.
IMPORTANT SAFETY INFORMATION: MONOVET® 90 (monensin Type A medicated article): Not for Human Use. Do not allow horses or other equines access to feeds containing monensin. Ingestion of monensin by horses has been fatal. Consumption by unapproved species may result in toxic reactions and even fatalities. A withdrawal time has not been established for pre-ruminating calves. Do not use in calves to be processed for veal. When mixing and handling Monovet 90, use protective clothing, impervious gloves and a dust mask. Operators should wash thoroughly with soap and water after handling. If accidental eye contact occurs, immediately rinse with water. To report adverse effects, access medical information, or obtain additional product information, call 1-877-426-7765. View product label here.
IMPORTANT SAFETY INFORMATION: TYLOVET® 100 (tylosin phosphate) TYPE A MEDICATED ARTICLE): Not for Human Use. Organisms may vary in their degree of susceptibility to any treatment. If no improvement is observed after the recommended treatment then a diagnosis and susceptibility should be reconfirmed. To ensure adequate mixing, an intermediate blending step should be used prior to manufacturing a complete feed. Do not use in any liquid feed containing sodium metabisulfite or in any supplement, concentrate or complete feed containing in excess of 2% bentonite. TYLOVET® 100 may be irritating to unprotected skin and eyes. When mixing and handling TYLOVET® 100 use protective clothing, impervious gloves, and a dust respirator. In case of accidental exposure, flush eyes with plenty of water. Exposed skin should be washed with plenty of soap and water. Remove and wash contaminated clothing. Seek medical attention if irritation becomes severe or persists. To report adverse effects, access medical information, or obtain additional product information call 1-877-426-7765. View product label here.